4Suppliers
7Customers
3Debt Items
20Related Chains

Century Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
FCDI FCDI 92% On March 23, 2021, we entered into a Manufacturing and Supply Agreement with FCDI, or, as amended, the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology tran…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos…
GDTC CytoMed Therapeutics Limited 72% Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
INAB IN8bio, Inc. 72% Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…

Century Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
BMY Bristol-Myers Squibb Company 90% Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: the sublicenses under the FCDI Agreem…
BMY Bristol-Myers Squibb Company 90% the sublicenses under the FCDI Agreements pursuant to our former Research Collaboration and License Agreement with Bristol-Myers Squibb dated January 7, 2022, or the Collaboration Agreement
FCDI FCDI 90% Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, we paid to FCDI (i) an upfront payment of $10.0 million, and will pay (ii) a percentage of any milestone payme…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE g…
GDTC CytoMed Therapeutics Limited 72% Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
INAB IN8bio, Inc. 72% Reciprocal relationship from INAB graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from INAB graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from INAB g…
TCRX TScan Therapeutics, Inc. 72% Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…

Century Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IPSC-DEBT Debt stack $43.6M 90% Market cache reports total debt of $43.6M.
IPSC-DEBT-10343 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
IPSC-DEBT-10342 Warrants outstanding: 16112 90% xbrl warrant detail from xbrl 2021-12-31.

Century Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Century Therapeutics, Inc..

Century Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
IPSC-OWNER-RA-CAPITAL-MANAGEMENT-L-P RA CAPITAL MANAGEMENT, L.P. 90% 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 75 tracked holders.

Century Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
ACET Adicet Bio, Inc. 100.00 2
TLSA Tiziana Life Sciences Ltd 100.00 2
AUTL Autolus Therapeutics plc 100.00 2
CRSP CRISPR Therapeutics AG 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
CRBU Caribou Biosciences, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 2
FATE Fate Therapeutics, Inc. 100.00 2 ['customer', 'supplier']
CTMX CytomX Therapeutics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
ATRA Atara Biotherapeutics, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
ARTV Artiva Biotherapeutics, Inc. 100.00 1 ['spend']